600664 Harbin Pharmaceutical Group
- 3.03
- -0.01-0.33%
Harbin Pharmaceutical Group News
Shareholders in Harbin Pharmaceutical Group (SHSE:600664) Have Lost 26%, as Stock Drops 5.0% This Past Week
Harbin Pharmaceutical Group (600664.SH): Currently, there are no traditional Chinese medicine milk tea products.
Harbin Pharmaceutical Group (600664.SH) stated on the investor interaction platform on September 5th that the company has products such as traditional Chinese medicine decoction pieces and protein powder, but currently does not have any traditional Chinese medicine milk tea products.
Huaan pharmaceutical group Co., Ltd.'s semi-annual report in 2024
Summary of the Mid-Year Report 2024 of Ha Yao Group Co., Ltd.
Harbin Pharmaceutical Group (600664.SH): plans to invest 10.06 million yuan to build the heating network project for the Nan Zhi Road factory area of Harbin Pharmaceutical Factory 6.
Harbin Pharmaceutical Group (600664.SH) announced on August 22nd that the company's subsidiary, Harbin Pharmaceutical Factory South Road Branch, will officially open to the public in early 2024. The museum is located at No. 326 South Direct Road, Daowai District, Harbin. After the relocation of the South Road Factory Area, it has been in a vacant state. In order to revitalize assets and improve asset utilization efficiency, the company plans to implement the South Road Factory Area heating network project, optimize the factory area heating system, and integrate it into the comprehensive cultural and tourism town infrastructure of the South Road Factory Area, in accordance with the company's overall planning for the factory area, and to maximize the utilization of the existing pipeline network.
Harbin Pharmaceutical Group (600664.SH): plans to invest 3.72 million yuan to implement the automation upgrade project of Sanjing Daqing Inspection Process.
On August 22, Gelonhui announced that its subsidiary, Sanjing Daqing, undertakes the manufacturing of the packaging material for the oral liquid product of Sanjing Pharmaceutical Group, the blue oral liquid bottle. The production base is located at 47 kilometers along the west main line of the production oilfield of the Honggang District in Daqing City. In order to improve the automation level of the production line and reduce production costs, the company plans to implement automated upgrade for the inspection process in the packaging workshop of Sanjing Daqing, increase automatic inspection and packaging linkage line, and replace the original manual inspection and packaging operations. The planned investment for this project construction is anticipated.
Harbin Pharmaceutical Group (600664.SH): its subsidiary's vitamin products on sale include Jian Anxi brand B vitamins capsule and so on.
Harbin Pharmaceutical Group (600664.SH) stated on the investor interaction platform on August 20 that its holding subsidiary, Jiananxi (Shanghai) Food Technology Co., Ltd. sells vitamin products, including Jiananxi brand B vitamins capsules.
There's No Escaping Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Muted Earnings Despite A 25% Share Price Rise
China Grants Harbin Pharmaceutical's Supplementary Drug Application for Antibiotic
Harbin Pharmaceutical Group (600664.SH): Its affiliated enterprise's injection-grade penicillin sodium has passed the generic drug consistency evaluation.
On August 7th, Gelunhui reported that Harbin Pharmaceutical Group's Pharmaceutical General Factory, an affiliate of Harbin Pharmaceutical Group, had received the "Drug Supplementary Application Approval Letter" for injection-grade penicillin sodium issued by the National Drug Administration. The product has passed the consistency evaluation of generic drug quality and efficacy. The main component of the injection-grade penicillin sodium is penicillin sodium, which is used for various infections caused by susceptible bacteria such as abscesses, septicemia, pneumonia, endocarditis, etc.
Harbin Pharmaceutical Group (600664.SH) plans to establish a joint venture with Qitaihe City Investment to carry out fermentation project construction.
On July 30th, Gelunhui reported that Harbin Pharmaceutical Group (600664.SH) plans to establish a joint venture with Qitaihe City Investment in Qitaihe City, in order to further improve the layout of the company's industry chain, enhance the integration advantage of raw materials and preparations, increase the company's product competitiveness, and conduct fermentation project construction. The registered capital of the joint venture is 0.145 billion yuan, the company contributes approximately 74.24 million yuan in equipment as capital, holding 51% of the joint venture's equity, and Qitaihe City Investment contributes 71.32 million yuan in cash, holding 49% of the joint venture's equity. This external investment is in line with the company's global strategy.
Harbin Pharmaceutical Group (600664.SH): currently has five main research and development entities.
Harbin Pharmaceutical Group (600664.SH) disclosed its investor relations activity record, which showed that the company currently has five main research and development subjects. It has established the Ha Yao Da Jiankang Research Institute, the Ha Yao Group Technology Center, and Ha Yao (Beijing) Biotechnology Co., Ltd. which focus on the research and development of OTC drugs, health products, generic drugs and innovative drugs, respectively. At the same time, the research and development teams for traditional Chinese medicine products and biological products are respectively focused on the upgrading of traditional Chinese medicine products and the development of biological products, forming a diversified research and development system.
Harbin Pharmaceutical Group (600664.SH): Plans to achieve revenue of 16.461 billion yuan in 2024, a year-on-year growth of 6.5%.
According to the investment relations activity record disclosed by Harbin Pharmaceutical Group (600664.SH) on July 18th, the company plans to achieve a revenue of 16.461 billion yuan in 2024, a year-on-year growth of 6.5%; the net income attributable to shareholders of the listed company excluding non-recurring gains and losses is 0.353 billion yuan, a year-on-year growth of 8.5%. At the same time, the company will control product production costs and various expenses and actively seek and cultivate new profit growth points. The above business goals do not represent the company's profit forecast for 2024, do not constitute the company's performance commitments to investors, and the company's actual operating conditions are subject to various internal and external factors.
Is Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Latest Stock Performance A Reflection Of Its Financial Health?
Announcement of Half-Year Performance Forecast Increase for HAECO Group Co., Ltd. in 2024.
Harbin Pharmaceutical Group (600664.SH) has issued a profit forecast, with an expected net income of 0.312 to 0.375 billion yuan, a year-on-year increase of 71% to 105%.
Harbin Pharmaceutical Group (600664.SH) has released a performance forecast for the first half of 2024, with the company expecting...
Harbin Pharmaceutical Group (600664.SH) appointed Vice President Meng Xiaodong as the Chief Financial Officer.
Harbin Pharmaceutical Group (600664.SH) announced that the company's Board of Directors recently received Liu Bo, the company's Vice President and CFO...
Harbin Pharmaceutical Group (600664.SH): compound sulfamethoxazole tablets pass the consistency evaluation of generic drugs.
On June 7th, Gelunhui reported that Harbin Pharmaceutical Group Co., Ltd. (Stock Code: 600664.SH) announced that pharmaceutical manufacturing plant #6, a subsidiary of the company (referred to as Harbin #6) received the "Drug Supplementary Application Approval Notice" for compound sulfamethoxazole tablets issued by the State Drug Administration of China (SDA) [Notice No.: 2024B02460], and the quality and efficacy of the product have been deemed consistent with that of the reference listed drug. Compound sulfamethoxazole tablet is a compound preparation composed of sulfamethoxazole and methoxybenzoin. Each tablet contains 0.4g of active ingredient sulfamethoxazole and 80mg of methoxybenzoin. The main indications are infections caused by sensitive strains, including 1. Coliform
Harbin Pharmaceutical Group (SHSE:600664) Has A Rock Solid Balance Sheet
Harbin Pharmaceutical to Upgrade Subsidiary's Production Line for 13 Million Yuan
Analysis
Price Target
No Data
No Data